Oslif Breezhaler (Indacaterol)

Indacaterol selectively activates beta2‑adrenergic receptors on airway smooth muscle, stimulating adenylate cyclase to raise cyclic AMP levels. The increased cAMP causes relaxation of the bronchial muscles, leading to prolonged bronchodilation that eases airflow obstruction in COPD patients.

The prescribed dose of Oslif Breezhaler is determined by the treating physician based on the patient’s clinical condition and response. The medication is delivered via a Breezhaler inhalation device, and the prescriber specifies the number of inhalations per day.

Safety of indacaterol in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oslif Breezhaler delivers indacaterol, a once‑daily LABA, offering prolonged bronchodilation with a convenient dosing schedule. Compared with short‑acting bronchodilators, it provides steadier airway support, while other LABAs may require twice‑daily dosing or different inhaler devices.

Store Oslif Breezhaler at ambient temperature below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not expose the inhaler to extreme heat or humidity, as this may affect powder integrity and device performance.

The medication is inhaled using the Breezhaler device. The patient removes a capsule, inserts it into the inhaler, and inhales forcefully through the mouthpiece as instructed. Proper technique, including a full exhalation before inhalation and a steady breath hold afterward, ensures optimal drug delivery.

Serious risks include paradoxical bronchospasm, severe hypersensitivity reactions such as angioedema, and cardiovascular events like arrhythmia or chest pain. Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or chest discomfort.

Oslif Breezhaler should be avoided in individuals with known hypersensitivity to indacaterol or any component of the formulation. Caution is advised for patients with significant cardiovascular disease, uncontrolled arrhythmias, or severe hepatic impairment, and it is not recommended for use in children.